HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Aquestive Therapeutics (NASDAQ:AQST) and maintained a $5 price target.
October 10, 2023 | 10:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aquestive Therapeutics (NASDAQ:AQST) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $5.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $5 indicates the firm's confidence in the stock's potential to reach this price in the short term. This could lead to increased investor interest and potentially a rise in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100